ClinConnect ClinConnect Logo
Search / Trial NCT00380848

Impact of Different Dialysis on Sleep Apnea in Patients With Renal Failure

Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Sep 25, 2006

Trial Information

Current as of August 02, 2025

Unknown status

Keywords

Sleep Apnea End Stage Renal Disease Hemodiafiltration

ClinConnect Summary

Sleep apnea or breathing problems during sleep are frequent, occurring in 6% of the general population. However, more than half of all patients on dialysis suffer from breathing problems related to sleep. Sleep apnea is associated with high blood pressure, excessive sleepiness, fatigue, poor memory and concentration as well as depression in those with normal kidneys.

Hemodiafiltration is a new kind of dialysis that is more efficient at clearing toxins that accumulate in kidney failure. It has been used successfully in Europe for over 15 years. However, the effects of hemodiafiltration on s...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients currently stable on a thrice weekly hemodialysis regimen for a minimum of 3 months
  • Patients with vascular access and no contraindications to anticoagulation
  • Presence of sleep-related breathing disorder defined as a mean apnea-hypopnea per hour of recording greater than 10 based on cardiorespiratory monitoring
  • Exclusion Criteria:
  • Patients already on hemodiafiltration therapy
  • Patients already on treatment for sleep disordered breathing.
  • Patients with significant neuromuscular disease
  • Patients with an expected lifespan \< 1 year
  • Patients unable to complete sleep related quality of life questionnaires and consent forms due to language barriers or dementia
  • Patients with known substance abuse
  • Patients with a respiratory disturbance index greater than 30 with active cardiovascular disease defined by unstable angina, myocardial infarction within 3 months or an Epworth sleepiness score greater than 15 while actively working in a stress situation (for example bus driver, taxi driver). These patients will be evaluated by a sleep specialist.
  • Living further than 30 km from dialysis centre

About Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre

The McGill University Health Centre (MUHC) and the Research Institute of the McGill University Health Centre (RI-MUHC) are leading institutions in clinical research and healthcare innovation. With a commitment to advancing medical knowledge and improving patient outcomes, the MUHC integrates cutting-edge research with high-quality patient care. The RI-MUHC fosters a collaborative environment where multidisciplinary teams engage in transformative research across various fields, including oncology, neurology, and cardiovascular health. By leveraging state-of-the-art facilities and a robust network of clinical expertise, both entities strive to translate scientific discoveries into effective treatments, ultimately enhancing the quality of life for patients locally and globally.

Locations

Montreal, Quebec, Canada

Patients applied

0 patients applied

Trial Officials

Kateri A Champagne, M.D.

Principal Investigator

McGill University Health Centre/Research Institute of the McGill University Health Centre

Navdeep Tangri, M.D.

Principal Investigator

McGill University

John R Kimoff, M.D.

Principal Investigator

McGill University Health Centre/Research Institute of the McGill University Health Centre

Paul Barre, M.D.

Principal Investigator

McGill University Health Centre/Research Institute of the McGill University Health Centre

Sameena Iqbal, M.D.

Principal Investigator

McGill University Health Centre/Research Institute of the McGill University Health Centre

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials